Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor. The course of NMOSD is driven by episodes of severe, sequential relapses leading to the accrual of permanent disability, while gMG is characterized by a heterogeneous collection of symptoms (including fatigue and muscle group weakness) which fluctuate over time.
Currently, no objective measurement tools exist to allow gMG and NMOSD patients to track their symptoms over time. Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms. If clinically validated, these measures could provide data to improve the remote monitoring of disease symptoms.
"We believe that empowering patients through real-time digital data sharing could strengthen communication between patients and healthcare professionals, and may enable more informed disease management decisions," said Dr. Guido Sabatella, Global Medical Lead in Neurology at Alexion.
"Easy-to-use digital tools have the potential to generate reliable and objective data to better understand the real impact of the disease on patients' lives and also have the potential to demonstrate the benefits of novel therapies to keep disease under control," explains Matthieu Lamy, Ad Scientiam's President.
Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG. Ongoing research will inform the development of a digital medical device intended to be used by patients as a self-assessment tool.
"International, multicenter, comparative studies against clinical gold standards, such as the Quantitative Myasthenia Gravis score and assessments of visual function, ambulation and dexterity in NMOSD, will be deployed to confirm the clinical relevance of selected digital biomarkers," according to Dr. Saad Zinaï, Ad Scientiam's Chief Medical Officer.
About Ad Scientiam
We strongly believe that continuously monitoring the progression of severe and disabling diseases in real life is crucial for delivering better care.
To achieve this, we create and clinically validate digital biomarkers that make visible these previously undetectable changes. These biomarkers are developed using data collected through smartphones and transformed using proprietary algorithms.
Hospital institutions such as the Paris Brain Institute (ICM) and pharmaceutical companies, including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis, trust us. In 2019, we launched MSCopilot®, the first CE-marked software medical device for the self-assessment of patients with multiple sclerosis. We are currently validating new devices in neuroscience, rare diseases, and mental disorders. Ad Scientiam is ISO 13485 certified.
Check our LinkedIn and Facebook page, or visit adscientiam.com.
Press contact: info@adscientiam.com
Contact Information:
Saad Zinaï
Chief Medical Officer
szinai@adscientiam.com
+33768008666
Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666
Related Files
FEB2023_Ad Scientiam digital biomarkers PR_Final_for Newswire.pdf
Related Images
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 1: Ad Scientiam Logo
This content was issued through the press release distribution service at Newswire.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond1.5.2024 18:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024 Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), Idorsia has improved the consent fee to 8’000’000 Idorsia shares up from 5’000’000. Other elements of the proposal published on April 23, 2024 such as the (i) amendment to the conversion price to CHF 6.00 (from currently CHF 33.95), (ii) extension of the maturity date by six months to January 17, 2025 and (iii) giving Idorsia the option to call the Bonds at par, in full or in part, at any time upon giving ten trading days' notice, remain unchanged. Bondholders can acc
MedAire Leads the Way in Enhanced Aviation Mental Health Support with MedAire Wellbeing Services Powered by Talk to a Peer1.5.2024 16:40:28 CEST | Press release
Phoenix, Arizona, May 01, 2024 (GLOBE NEWSWIRE) -- May 1, 2024 – MedAire, the foremost provider of aviation medical and security services, is excited to announce the introduction of MedAire Wellbeing Services in a pioneering collaboration with OdiliaClark, leaders in impairment risk management and workplace wellbeing. This initiative sets a new standard for peer support within the business aviation sphere, offering a targeted approach to mental health and wellbeing tailored for aviation professionals. The FAA Mental Health & Aviation Medical Clearances Aviation Rulemaking Committee's (ARC) recent deliberations on mental health in aviation highlighted the critical need for peer support enhancements beyond traditional Employee Assistance Programs (EAPs). Aligning with this foresight, MedAire Wellbeing Services offers a sophisticated peer support system tailored to the distinct needs of aviation crews. "MedAire has been the go-to resource for aviation professionals, ensuring their health
Annual General Meeting 20241.5.2024 16:26:48 CEST | Press release
COMPANY ANNOUNCEMENT NO 13/2024 - May 1, 2024 On Tuesday, 30 April 2024 at 4 pm CEST Royal Unibrew A/S held its Annual General Meeting at which the below resolutions were adopted. Agenda and full contents of the proposals: 1.Report on the Company’s business activities during the year The Board of Directors’ report was noted. 2.Presentation of the audited Annual Report for 2023 for approval The Company’s Annual Report for 2023 was adopted by the Annual General Meeting. 3.Resolution to discharge the Board of Directors and the Executive Management from liability The General Meeting adopted the resolution to discharge the Board of Directors and the Executive Board from liability in relation to the approved Annual Report 2023. 4.Proposed distribution of profit for the year, including resolution on the amount of dividend The General Meeting adopted the Board of Directors’ proposal that no ordinary dividend is paid out and that the net profit of DKK 1,095 million is to be carried forward. 5.P
Ændring af selskabskapital1.5.2024 16:21:36 CEST | pressemeddelelse
Selskabsmeddelelse nr. 15/2024 Peberlyk 4 DK-6200 Aabenraa Telefon +45 74 37 37 37 Sydbank A/S CVR-nr. DK 12626509, Aabenraa sydbank.dk 1. maj 2024 Ændring af selskabskapital På Sydbank A/S’ ordinære generalforsamling den 21. marts 2024 blev det besluttet at nedsætte bankens selskabskapital med nominelt 19.119.000 kr. ved annullering af 1.911.900 stk. aktier, som blev erhvervet under bankens aktietilbagekøbsprogram i 2023. Kreditorernes frist for at anmelde krav er udløbet, og bestyrelsen har efterfølgende besluttet at gennemføre kapitalnedsættelsen. Kapitalned-sættelsen vil blive registreret i Erhvervsstyrelsen. Sydbanks samlede selskabskapital udgør herefter nominelt 545.884.200 kr. svarende til 54.588.420 aktier a 10 kr. (54.588.420 stemmerettigheder). Som følge af kapitalnedsættelsen er bankens vedtægter ændret for så vidt angår selskabskapitalens størrelse. De reviderede vedtægter kan ses på sydbank.dk og sydbank.com. Venlig hilsen Sydbank A/S Vedhæftet fil SM 15
Change of share capital1.5.2024 16:21:36 CEST | Press release
Company Announcement No 15/2024 Peberlyk 4 6200 Aabenraa, Denmark Tel +45 74 37 37 37 Sydbank A/S CVR No DK 12626509, Aabenraa sydbank.dk 1 May 2024 Dear Sirs Change of share capital At the AGM of Sydbank A/S held on 21 March 2024 it was resolved to reduce the Bank’s share capital by nominally DKK 19,119,000 by cancelling 1,911,900 shares which were purchased under the Bank’s share buyback programme in 2023. The creditors’ time limit for filing claims has expired and the Board of Directors has subsequently decided to implement the capital reduction. The capital reduction will be registered with the Danish Business Authority. Sydbank’s total share capital represents nominally DKK 545,884,200, equal to 54,588,420 shares of DKK 10 each (54,588,420 voting rights). As a result of the capital reduction the Bank’s Articles of Association have been amended with respect to the size of the share capital. The revised Articles of Association are available at sydbank.dk and sydbank.com. Yours since